All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

benzathine benzylpenicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	4347	1538-09-6

Description:

Molecule	Description
Synonyms: benzathine benzylpenicillin penicillin G benzathine benzylpenicillin benzathine benzylpenicillin benzathine hydrate stelues	Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine. Molecular weight: 909.13 Formula: C48H56N6O8S2 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 89.54 ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
3.60	g	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 27, 1952	FDA	KING PHARMS
Dec. 1, 2010	PMDA	MDKKK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	161.52	47.73	66	410	310621	63177925
Embolia cutis medicamentosa	70.58	47.73	10	466	417	63488129
Congenital syphilis	51.68	47.73	5	471	3	63488543

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Embolia cutis medicamentosa	340.83	40.83	42	655	197	34956037
Jarisch-Herxheimer reaction	57.52	40.83	10	687	581	34955653

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Embolia cutis medicamentosa	373.45	32.10	49	1083	587	79742669
Drug hypersensitivity	110.02	32.10	62	1070	298854	79444402
Jarisch-Herxheimer reaction	62.73	32.10	11	1121	946	79742310

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01CE08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase sensitive penicillins
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:53000	epitope role
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Scarlet fever	indication	30242009	DOID:8596
Pneumonia due to Streptococcus	indication	34020007
Erysipelas	indication	44653001	DOID:11330
Syphilis excluding neurosyphilis	indication	76272004
Streptococcal infectious disease	indication	85769006
Pneumococcal pneumonia	indication	233607000
Streptococcus pyogenes infection	indication	302809008
Kidney disease	contraindication	90708001	DOID:557
Infectious mononucleosis	contraindication	271558008	DOID:8568
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Bacterial infections	Indication
Cattle	Bacterial pneumonia caused by Streptococcus spp	Indication
Cattle	Bacterial pneumonia caused by Actinomyces pyogenes	Indication
Cattle	Bacterial pneumonia caused by Staphylococcus aureus	Indication
Cattle	Upper respiratory infections caused by A pyogenes	Indication
Cattle	Blackleg (Clostridium chauvoei)	Indication
Cattle	Prophylaxis of bovine shipping fever	Indication
Dogs	Bacterial infections	Indication
Horses	Bacterial infections	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Longicil Fortified	Zoetis Inc.	2
Dura-biotic, Flo-cillin	Zoetis Inc.	2
Dual-Cillin, Pen BP-48	Huvepharma EOOD	2
Combi-PEN-48	Bimeda Animal Health Limited	2

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Beta-lactamase TEM	Enzyme		BLAT_ECOLX		Ki	4.70		CHEMBL

External reference:

ID	Source
4017439	VUID
N0000145827	NUI
41372-02-5	SECONDARY_CAS_RN
4017439	VANDF
4017440	VANDF
C0030829	UMLSCUI
CHEBI:51352	CHEBI
CHEBI:18208	CHEBI
CHEMBL3989515	ChEMBL_ID
CHEMBL1200651	ChEMBL_ID
25137901	PUBCHEM_CID
7980	RXNORM
5244	MMSL
d07727	MMSL
002683	NDDF
004977	NDDF
323389000	SNOMEDCT_US
323404007	SNOMEDCT_US
75247008	SNOMEDCT_US
78507004	SNOMEDCT_US
D010401	MESH_DESCRIPTOR_UI
C0030827	UMLSCUI
DB01053	DRUGBANK_ID
5904	PUBCHEM_CID
RIT82F58GK	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1016	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1016	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1016	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1666	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1666	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1666	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	25 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	50090-1815	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	24 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5932	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	22 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-600	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-600	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-601	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	60793-601	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN C-R 900/300	HUMAN PRESCRIPTION DRUG LABEL	2	60793-602	INJECTION, SUSPENSION	900000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN C-R 900/300	HUMAN PRESCRIPTION DRUG LABEL	2	60793-602	INJECTION, SUSPENSION	900000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-700	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-700	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-701	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-701	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-702	INJECTION, SUSPENSION	2400000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	60793-702	INJECTION, SUSPENSION	2400000 [iU]	INTRAMUSCULAR	NDA	26 sections
BICILLIN L-A	HUMAN PRESCRIPTION DRUG LABEL	1	68071-1824	INJECTION, SUSPENSION	1200000 [iU]	INTRAMUSCULAR	NDA	24 sections
BICILLIN CR	HUMAN PRESCRIPTION DRUG LABEL	2	68258-8910	INJECTION, SUSPENSION	600000 [iU]	INTRAMUSCULAR	NDA	24 sections